Edimer Pharmaceuticals
Latest round
- Series B
Last raised
- Jul 2013
Total raised
- $32M
Investors
- 4
About Edimer Pharmaceuticals
Edimer Pharmaceuticals focuses on developing innovative therapies to meet unmet medical needs, primarily in the realm of rare diseases.Edimer Pharmaceuticals, founded in 2009, is based in Cambridge, US. The company specializes in developing therapies for rare diseases.11 mn.Edimer Pharmaceuticals offers a range of pharmaceutical products primarily focused on innovative therapies aimed at addressing unmet medical needs in various therapeutic areas. The company's core offerings include specialty medications that target specific conditions and improve patient outcomes. These products are designed for diverse end-use cases, such as treating rare diseases and enhancing the quality of life for patients suffering from complex health issues. The company serves a wide array of clients, including healthcare providers, hospitals, and specialty pharmacies, with end users comprising patients requiring specialized care.Revenue generation for Edimer Pharmaceuticals is structured around direct-to-consumer sales as well as partnerships with healthcare providers and specialty pharmacies. The company engages in business transactions through a model that includes the sale of its flagship therapeutic products, which may involve pricing plans based on volume purchases or subscription services for healthcare professionals. Clients typically place orders directly through the company's platform or via authorized distributors, ensuring a streamlined procurement process. Revenue is driven by the demand for specialized medications, which are key to addressing specific medical conditions, aligning with the company's mission to deliver effective healthcare solutions. The company is also exploring expansion into European markets to meet growing demand for its innovative treatments. This strategic initiative aims to enhance its geographical presence and drive revenue growth, ensuring that the company can address the needs of patients in diverse regions. Specific timelines for product launches and market entry are not disclosed.
Who invested in Edimer Pharmaceuticals
4 investors across 2 rounds
See all investors in Edimer Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Edimer Pharmaceuticals
Who invested in Edimer Pharmaceuticals?
Edimer Pharmaceuticals has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Edimer Pharmaceuticals raised?
Edimer Pharmaceuticals has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Edimer Pharmaceuticals last raise money?
Edimer Pharmaceuticals's most recent round on record is a Series B, in Jul 2013.
What does Edimer Pharmaceuticals do?
Edimer Pharmaceuticals focuses on developing innovative therapies to meet unmet medical needs, primarily in the realm of rare diseases.
Where is Edimer Pharmaceuticals headquartered?
Edimer Pharmaceuticals is headquartered in Cambridge, US.
Which VCs invest in companies like Edimer Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Edimer Pharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Edimer Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.